Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10949151 | 0.84 | KCNA5 (0.49) | ALDH1A1MEN1KMT2AKDM4ETRPM8 | |
| SCHEMBL2481928 | 0.83 | TRPM8 (0.40) | CYP19A1ALDH1A1TRPM8TRPA1KCNA5 | |
| SCHEMBL5182007 | 0.82 | TRPM8 (0.39) | CYP19A1ALDH1A1TRPM8TRPA1KCNA5 | |
| SCHEMBL6235069 | 0.82 | TRPM8 (0.39) | CYP19A1ALDH1A1TRPM8TRPA1KCNA5 | |
| SCHEMBL1903958 | 0.79 | KCNA5 (0.39) | CYP19A1ALDH1A1TRPM8TRPA1KCNA5 | |
| SCHEMBL8470258 | 0.78 | KCNA5 (0.38) | CYP19A1ALDH1A1TRPM8TRPA1KCNA5 | |
| SCHEMBL31752406 | 0.77 | TRPM8 (0.46) | ALDH1A1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL10363050 | 0.76 | KCNA5 (0.42) | ALDH1A1MEN1KMT2AKDM4ETRPM8 | |
| SCHEMBL10363049 | 0.76 | KCNA5 (0.42) | ALDH1A1MEN1KMT2AKDM4ETRPM8 | |
| SCHEMBL5118235 | 0.75 | ALDH1A1 (0.42) | CYP19A1ALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0598383-B1 | Process for the preparation of 5,6-diacetoxyindole | BRISTOL MYERS SQUIBB CO (US) | 1999-02-03 | — | — | EP | claimed |
| JP-55045629-A | — | — | None | — | — | JP | disclosed |
| US-8722881-B2 | Method of synthesis of tetradentate amide macrocycle ligand and its metal-complex | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2014-05-13 | — | — | US | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20110094043-A1 | Method of synthesis of tetradentate amide macrocycle ligand and its metal-complex | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS | 2011-04-28 | — | — | US | disclosed |
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| EP-1841768-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| US-5527900-A | VIRICIDES; ANTI-HTLV ACTIVITY | STITCHING REGA VZW (BE) | 1996-06-18 | — | — | US | disclosed |
| US-5026625-A | Photoinitiators for polymerization of ethylenically unsaturated compounds | CIBA-GEIGY CORPORATION (US) | 1991-06-25 | — | — | US | disclosed |
| EP-0222192-A2 | Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil | Sloan-Kettering Institute For Cancer Research (US) | 1987-05-20 | — | — | EP | disclosed |
| JP-S5545629-A | PREPARATION OF 4-AMINOPYRIDINE | NIPPON SODA CO LTD | 1980-03-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | CYP19A1 3556/4885ALDH1A1 2112/4885MEN1 4812/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CYP19A1 1781/4885ALDH1A1 2864/4885MEN1 4232/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CYP19A1 1781/4885ALDH1A1 2864/4885MEN1 4232/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | CYP19A1 1271/4885ALDH1A1 201/4885MEN1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.